News Sandoz says it is entering "golden decade" in biosimilars Sandoz said today it intends to double net sales between 2025 and 2035, fuelled by an acceleration in biosimilar medicine development.
Digital The cliff was never the crisis: Pharma’s strategy problem The patent cliff isn't the problem. It's the symptom.
Sales & Marketing The hidden risks of biotech layoffs: Why cost-cutting trigge... Reducing your team without a strategic risk plan actually spikes corporate vulnerability more than it lowers burn rates.
R&D Sponsored From Alzheimer’s disease research to the real-world setting:... In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.
News Activist investor renews its criticism of Novavax Shah Capital has fired another broadside at vaccine firm Novavax, accusing its board and management of a "destruction in shareholder value."
News Investor seeks sale of Novavax after poor COVID jab sales Investor Shah Capital has called on Novavax's board to put the company up for sale, citing a "litany of missteps" at the vaccine developer.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.